Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 15 Feb 24 25-NSE Exchange delisting
- 9 May 22 425 Business combination disclosure
- 27 Apr 22 425 Business combination disclosure
- 19 Apr 22 425 Business combination disclosure
- 18 Apr 22 425 Business combination disclosure
- 18 Apr 22 425 Business combination disclosure
- 18 Apr 22 EFFECT Notice of effectiveness
- 15 Apr 22 424B3 Prospectus supplement
- 11 Apr 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 6 Apr 22 S-4/A Registration of securities issued in business combination transactions (amended)
-
25 Mar 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 8 Mar 22 S-4 Registration of securities issued in business combination transactions
CMRA similar filings
Filing view
External links
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the use in this Amendment #1 to the Registration Statement on Form S-4 of Comera Life Sciences Holdings, Inc. of our report dated March 8, 2022, relating to the financial statements of Comera Life Sciences, Inc., which includes an explanatory paragraph relating to the Company’s ability to continue as a going concern, appearing in the Prospectus which is a part of this Registration Statement.
We also consent to the reference to our firm under the heading “Experts” in such Registration Statement.
/s/ BAKER TILLY US, LLP
Tewksbury, Massachusetts
March 25, 2022